Citi lifts its target for Novavax stock to USD 8.00

Published on 10/20/2026 at 20:06 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Novavax set a USD 255.00 million 2026 midpoint on August 6. Novavax stock is EUR 10.15 on October 20, 2026, up 1.60 percent versus Tradegate.

Citi target and reporting date

On October 15, 2026, Citi raised its Novavax target from USD 7.00 to USD 8.00.
Novavax set a USD 255.00 million midpoint for its 2026 adjusted revenue outlook on August 6, 2026.
Novavax stock stands at EUR 10.15 at Lang & Schwarz on October 20, 2026 at 8:02 p.m. CEST, up 1.60 percent versus the Tradegate close of October 16, 2026.
Novavax is scheduled to report third-quarter 2026 results on November 5, 2026.

NVAX, US6700024010, Illustration mit AI erstellt.

Citi analyst Geoff Meacham raised Novavax's price target from USD 7.00 to USD 8.00 on October 15, 2026, while keeping a Sell rating, Markets Insider reported. The target remains below the latest Nasdaq quote. Novavax stock stood at EUR 10.15 at Lang & Schwarz on October 20, 2026 at 8:02 p.m. CEST, up 1.60 percent versus the Tradegate close of October 16, 2026 at EUR 9.99.

Revenue outlook reaches USD 275 million

The company's latest financial outlook centers on adjusted total revenue of USD 235 million to USD 275 million for 2026, with a USD 255 million midpoint. The framework was raised during the second-quarter update on August 6, 2026, and excludes Sanofi supply sales, royalties and milestones, according to the earnings-call transcript published by Benzinga.

What does the USD 8.00 target imply?

Using the USD 11.40 Nasdaq quote at 2:05 p.m. EDT on October 20, 2026, Citi's USD 8.00 target sits 29.82 percent below the market price. The distance makes the rating change a cautious signal rather than a bullish valuation call. The primary listing is Nasdaq, and Novavax identifies itself as NASDAQ:NVAX on its investor-relations site.

Price position and reporting date

On October 16, 2026, the stock closed at USD 11.26 on Nasdaq, 15.90 percent below its USD 13.39 52-week high and 81.60 percent above its USD 6.20 low. The same market snapshot put year-to-date performance at plus 67.60 percent and market capitalization at USD 1.86 billion. Novavax is scheduled to report third-quarter 2026 results on November 5, 2026, with consensus earnings per share estimated at minus USD 0.33.

Valuation stays loss-based

Novavax's trailing earnings remain negative, so a meaningful price-to-earnings ratio is not available for comparison. The next report will test whether the 2026 outlook can absorb seasonal vaccine timing and the company's shift toward partner-led revenue.

Stock context

For investors, the central contrast is clear: the stock is up 67.60 percent year to date, while Citi's revised target remains USD 3.40 below the latest Nasdaq quote. That gap puts the analyst action and the November 5 reporting date at the center of the next valuation check.

Trading level and next date

Novavax stock stood at EUR 10.15 at Lang & Schwarz on October 20, 2026 at 8:02 p.m. CEST, up 1.60 percent versus the Tradegate close of October 16, 2026 at EUR 9.99. The next scheduled reporting date is November 5, 2026.

The further course of trading is shown by the continuously updated real-time quote of Novavax stock.